AdaptHealth: The Kaiser Deal Trap, The Diabetes Sale, And The Question At $6

AdaptHealth (AHCO) is scheduling three investor conferences in mid-September. That's the headline. The context behind it tells a much more useful story. The home medical equipment company has spent the past six months in free fall — the stock has dropped roughly 50% from its April 2026 highs — and management is heading to the sell-side to answer one question: has the business fundamentally broken, or is this a painful transition through which the company can emerge leaner and more focused?

The short answer from the evidence: AdaptHealth is navigating three simultaneous blows that collided in the second quarter of 2026. The company's biggest strategic bet — a capitated contract with Kaiser Permanente — is compressing margins more and longer than anyone expected. It's selling off its diabetes business, which shrinks the revenue base. And it's taking manufacturer price increases it can't pass through. The question for an investor isn't whether the company is in trouble. It's whether the stock price has priced in the trouble already.

Let me walk through what happened and in what order.

The earnings bomb

In late April 2026, AdaptHealth was having a good year. The company had just refinanced $1.1 billion of debt at better rates, completed the rollout of a massive new contract with Kaiser Permanente covering 10 million members, and raised its full-year revenue guidance to $3.45–$3.52 billion. The stock was near its 52-week high of $13.38.

Then everything went sideways at once.

On August 4, AdaptHealth reported Q2 results that missed on every major metric. Revenue came in at $740.3 million versus a Wall Street estimate of roughly $847 million. The company posted a loss of $0.99 per share versus an expected profit of $0.15. The net loss of $145 million was partly mechanical — a $144 million goodwill write-down — but that's a symptom, not the disease. The underlying problem was that adjusted EBITDA fell 3.2% year-over-year to $132 million, even as revenue grew 12.7%.

Then management slashed full-year guidance. Revenue was cut from a $3.49 billion midpoint to $2.87 billion. Adjusted EBITDA guidance was slashed from $680–$730 million to $490–$520 million. Free cash flow was halved from $175–$225 million to $80–$120 million. The stock fell roughly 26% on the day and has continued sliding, now trading around $6.

Three things went wrong simultaneously

The guidance cut wasn't one problem. Management broke it down into four specific hits, and understanding them matters because they don't all behave the same way going forward.

The Kaiser deal's margin trap. The five-year capitated contract with Kaiser Permanente — announced in August 2025 as a game-changer — is the biggest piece. Under a capitated model, AdaptHealth receives a fixed per-member-per-month fee and assumes the risk for managing all home medical equipment utilization for those members. It sounds like a great deal: predictable revenue, 10 million members, a five-year horizon. The problem is the unit economics. Management said the contract is hitting EBITDA by roughly $55 million this year. The transition required massive hiring, overtime, contract labor, and infrastructure spend — opening locations, buying vehicles, recruiting 1,000 employees — all before the revenue started flowing. Even now that the transition is "complete," the margins on this deal are below where the company needs them to be. CEO Suzanne Foster called the transition "complex." That's a polite way of saying the economics don't work the way they assumed.

This matters because capitated revenue is supposed to grow toward 15% of the business by year-end. If the margins on this model are thin or negative, growing it faster makes the problem bigger, not smaller.

The diabetes sale. In July, AdaptHealth agreed to sell its Diabetes Health business to Cardinal Health for $235 million in cash. The business is being classified as discontinued operations. On the surface, this is rational: diabetes was a slow-growth segment, and $235 million in cash reduces debt. But it has a double accounting impact. The sale removes roughly $100 million of annual revenue from the top line, and about $60 million of that was corporate overhead that Diabetes Health was absorbing. That overhead doesn't disappear — it gets reallocated to the remaining businesses. Management said roughly half of it can be eliminated over 12 months, but the remaining $30 million hits the other segments' margins. So a move that should strengthen the business temporarily weakens the financials.

Manufacturer price increases. A $30 million hit from a supplier raising prices. AdaptHealth has historically had limited pricing power because it serves patients through Medicare, Medicaid, and commercial insurers, all of whom set reimbursement rates. When your costs go up and your revenue is largely regulated, the margin takes the hit. This one is less structural than the Kaiser deal, but it signals the kind of squeeze that HME companies face when they can't control either side of the spread.

Other portfolio actions. A $15 million hit from unspecified restructuring and wind-down activities. Small relative to the others, but it adds up.

Combined, these four factors account for roughly $200 million of EBITDA destruction versus the original plan. That's a 28% reduction in the profit target, and it explains the guidance cut.

What the investor conferences are really for

Management's appearances at the Jefferies, Baird, and Deutsche Bank conferences on September 14, 15, and 17 aren't routine. This is damage control and expectation-resetting after the worst earnings-driven selloff in the company's recent history. The CEO and CFO are going to tell analysts the same story the Q2 transcript implied: the Kaiser deal is transitioning, margins will recover, the diabetes sale delivers cash, the core sleep and respiratory businesses are still growing.

But here's the question no conference presentation can fully answer: will they?

The structural tension

To evaluate whether the stock's decline has gone too far, you need to look past the quarter and ask whether the business model itself is broken or just bruised.

On the positive side: organic revenue growth was 15.9% in Q2, with growth across all segments. The Kaiser deal, despite its margin pain, locks in 10 million members for five years and creates a durable revenue base. The diabetes sale delivers $235 million in cash. The company completed a $1.1 billion debt refinancing in April with improved terms and an extended maturity into 2031. Management promised 20% enterprise margins by year-end and completed a workforce restructuring that should save $19 million annually.

On the negative side: the Kaiser deal's economics remain uncertain, and it's growing toward 15% of the business on a potentially sub-marginal basis. The company is losing roughly $48 million in free cash flow year-to-date — compared with $73 million of FCF in the same period last year. The $60 million in corporate overhead from the diabetes sale doesn't vanish; it gets reallocated. Manufacturer price increases suggest ongoing margin pressure in a regulated pricing environment. And the guidance cut was massive — management was optimistic in April and has had to walk it back nearly $600 million in revenue and $200 million in EBITDA. That's credibility damage.

The stock at $6 represents a market cap of roughly $1 billion. That's down from roughly $2.2 billion at the April highs. At the new guidance midpoint of $505 million in EBITDA, that's roughly a 2x EV/EBITDA multiple. That's cheap for a home healthcare business. But cheap for a reason — and the question is whether that reason is a transition or a trap.

The valuation test

A 2x EBITDA multiple makes sense only if the market believes the business will stay in this rough patch for a long time. If the Kaiser deal normalizes, the diabetes overhead gets cut in half, the $19 million in restructuring savings materialize, and the core businesses keep growing at the mid-single-digit organic rate they've shown, then 2027 EBITDA could approach $600–$650 million. At today's market cap, that would value the company at roughly 1.5–1.7x forward EBITDA. For a diversified HME operator with 670 locations, 4.5 million patients, and a five-year government-backed revenue stream, that's a level where patient buyers start paying attention.

But this all depends on the Kaiser deal not deteriorating further and on management actually delivering the margin recovery they're promising. The company has been here before — in Q4 2025, operating margins contracted from 11.4% to negative 8.7%, and the stock sold off on profitability concerns even though revenue beat. AdaptHealth has a history of promising margin expansion and then finding friction.

The balance sheet also needs watching. The company carries roughly $1.1 billion in debt under its new credit facility, with a covenant requiring a maximum leverage ratio of 3.5x. At current EBITDA levels, that's not a problem. But if earnings continue to miss and the company starts burning through its revolver, the leverage ratio and the cost of capital become a second-order risk.

Where this lands

AdaptHealth isn't the same company it was in April 2026, when it was growing, raising guidance, and trading near $13. The Kaiser deal turned out to be a margin drag instead of a margin driver. The diabetes sale, while strategically sensible, reduces the revenue base and reallocates overhead. And the company is losing cash instead of generating it.

But at $6 and a 2x EBITDA multiple, the market has already priced in a version of the business that's stuck in this pain. The bull case — that this is a transition period through which a structurally solid HME operator emerges leaner, with $235 million in cash, a restructured cost base, and a Kaiser contract that eventually delivers — doesn't require a perfect outcome. It just requires the margin recovery to happen within the next two to three quarters, and for the Kaiser deal to stabilize at something better than a loss leader.

The bear case is equally visible: the capitated model doesn't work at these volumes, the overhead from the diabetes sale proves harder to cut, manufacturer costs keep rising, and the next two quarters show further margin deterioration instead of recovery. In that scenario, the current price still has room to fall, and the cheap multiple is cheap for a structural reason.

The September conference appearances won't resolve this question — they're management's attempt to convince investors the bull case is right. The resolution comes in the third quarter earnings report, expected in November. That quarter will show whether the Kaiser deal's margins are trending toward the 20% target or still dragging. It will show whether the diabetes overhead is being cut. And it will show whether free cash flow is recovering toward the $80–$120 million guidance range.

Until then, the stock is cheap but unproven. The valuation is a bridge — but it only works if the business on the other side is the one management is describing.